Experts are now urging the FDA to ban the use of phenylpropanolamine (PPA) in OTC products
Experts are now urging the FDA to ban the use of phenylpropanolamine (PPA) in OTC products.
This is due to a possible increased risk of hemorrhagic stroke...especially in young women taking high doses for weight loss.
For now, warn patients not to exceed recommended doses of PPA-containing products...Acutrim, Dexatrim, Contac, Dimetapp, etc.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote